Behind every quarterly headline sits a portfolio, and the Biogen Q3 2026 results, announced on 28 October 2026, are a good example. Revenue rose 11% to $2,804.1 million, but the more interesting story is which medicines drove it, which declined, and which late-stage trials could change the picture. Biogen’s Growth Portfolio, spanning Alzheimer’s, rare neurological disease, postpartum depression and eye disease, grew 49%, while its older multiple sclerosis franchise shrank. This article looks at the portfolio and the pipeline, and is careful to separate reported sales from clinical promise.
Key takeaways: Biogen Q3 2026 results by product and pipeline
- Growth Portfolio revenue was about $1.26 billion, up 49%, roughly 63% of core pharmaceutical revenue.
- Multiple sclerosis product revenue fell 13% to $919.3 million.
- Syfovre and Empaveli, from the Apellis acquisition, added $191.3 million and $51.5 million.
- Phase 3 lupus data for litifilimab are due in the first half of December 2026.
- Non-GAAP EPS fell to $2.62 from $4.81, with GAAP EPS a loss of $0.14.
The growth drivers in the Biogen Q3 2026 results
Several products moved the total. Spinraza, for spinal muscular atrophy, generated $460.6 million, up 23%. Skyclarys, for Friedreich’s ataxia, reached $178.2 million, up 34%. Zurzuvae, for postpartum depression, rose 53% to $84.4 million, and Qalsody, for a genetic form of ALS, rose 42% to $37.5 million. Together, these medicines illustrate Biogen’s pivot from a multiple sclerosis-centred business toward rare and neurological conditions. The company’s own figures are on the Biogen investor relations site.
Leqembi in the Biogen Q3 2026 results
Leqembi, the Alzheimer’s therapy developed with Eisai, is a bellwether for sentiment. Biogen recorded its 50% share of $68.4 million, up 60%, while Eisai, which books the global in-market sales, reported $202 million, up 67%. The gap between the two numbers is simply an accounting split. Uptake of Alzheimer’s treatments depends on diagnosis, infusion capacity and monitoring, and growth from a small base can look impressive. The company has not given patient numbers in the material we reviewed.
The declining franchise in the Biogen Q3 2026 results
Multiple sclerosis medicines remain large but are under pressure. Tysabri generated $437.1 million, up 1%, Vumerity $192.0 million, down 11%, and the franchise overall $919.3 million, down 13%. As older products face competition, the growth portfolio must expand faster than the legacy decline to sustain total revenue growth. In this quarter it did, helped by acquisitions.
Acquired eye-disease products in the Biogen Q3 2026 results
Biogen closed its Apellis acquisition in May 2026. Syfovre, a treatment for geographic atrophy, an advanced form of dry age-related macular degeneration, contributed $191.3 million, and Empaveli $51.5 million. Prior-year comparisons use Apellis’s own filings. See also our Pharmaceutical section.
What the Biogen Q3 2026 results say about neurology drug demand
Sales are a measure of demand, not of clinical value. Strong growth in rare-disease medicines such as Spinraza and Skyclarys reflects diagnosed patients with few alternatives, and these products are priced accordingly. Growth in Zurzuvae suggests uptake in postpartum depression, a condition where oral options were limited. Alzheimer’s therapies face a different picture, because diagnosis, imaging and infusion logistics are bottlenecks. For clinicians, the quarter is a reminder that access, reimbursement and monitoring requirements shape how quickly approved therapies reach patients, and that sales growth does not on its own show better outcomes.
The pipeline catalysts after the Biogen Q3 2026 results
The next set of readouts could matter more than the quarter. Litifilimab, for systemic lupus erythematosus, has two Phase 3 studies, TOPAZ-1 and TOPAZ-2, with topline results expected in the first half of December 2026. Litifilimab in cutaneous lupus and felzartamab are expected to read out in the first half of 2027, and zorevunersen for Dravet syndrome in the third quarter of 2027. Trial listings are available on ClinicalTrials.gov. These are investigational medicines; none is approved for these uses on the basis of the information reviewed.
Earnings detail in the Biogen Q3 2026 results
While sales rose, non-GAAP net income fell to $391.4 million from $707.5 million, and the GAAP result was a net loss of $20.6 million. Biogen attributed $284 million to acquired in-process R&D and related charges, mostly from the RayThera acquisition. Full-year non-GAAP EPS guidance is $12.20 to $13.00, with the low end raised from $12.00 after a July cut from $15.25 to $16.25. We read that as a modest adjustment.
Questions the Biogen Q3 2026 results leave open on the pipeline
What do the lupus studies need to show for litifilimab to matter commercially, and how large is that market? How will Leqembi uptake change as diagnostic tools improve? Can the eye-disease products grow beyond their current base under Biogen’s ownership? What further deals are planned, and what would they add in charges? The company announcement does not address these questions, and we have not guessed at answers.
Market data from Acumen Research and Consulting
Acumen Research and Consulting’s Biopharmaceutical Market report estimates the global market at USD 328 billion in 2021 and USD 853 billion by 2030, a CAGR of 11.3%, with North America over 33% in 2021 and monoclonal antibodies about 32%. The report is broad and dated, and does not address neurology specifically or Biogen.
Timeline of the Biogen Q3 2026 results and pipeline
- May 2026: Apellis acquisition closes.
- 28 October 2026: third-quarter results.
- First half of December 2026: litifilimab SLE Phase 3 topline.
- First half of 2027: cutaneous lupus and felzartamab readouts.
- Third quarter of 2027: zorevunersen Phase 3.
General background: why portfolio mix matters
A pharmaceutical company’s resilience depends on how quickly new products replace those losing exclusivity or share. A healthy mix reduces dependence on a single franchise.
Our analysis of the Biogen Q3 2026 results
In our assessment, the Biogen Q3 2026 results show a portfolio in transition: strong growth in newer drugs, decline in multiple sclerosis, and acquisitions adding both revenue and charges. The pipeline readouts are the real tests.
What is not disclosed in the Biogen Q3 2026 results
- Patient numbers for Leqembi.
- Organic versus acquired growth.
- Trial outcomes.
Risks and caveats
Trials may fail, and company figures are not independently verified here. This article is news reporting and not medical or investment advice.
What to watch next
- December lupus data.
- Leqembi uptake.
- MS franchise decline rate.
FAQ
What drove growth?
The Growth Portfolio, up 49%, and Apellis products.
Which drugs declined?
Vumerity and the multiple sclerosis franchise overall.
When is the next big readout?
Litifilimab lupus Phase 3 topline in the first half of December 2026.
How we reported this: we relied on the company announcement, trial registries and the Acumen Research and Consulting report cited above. Our calculations are labelled. Last updated 29 October 2026. This is news reporting and not advice.
